Review for the St Gallen international expert consesus from 2003 to 2013        GAO Guo-xuan, XIN Ling, LIU Qian, et al. Breast Disease Certer, Peking University First Hospital, Beijing 100034, China
Corresponding author: LIU Yin-hua,E-mail：liuyinhua@medmail.com.cn
Abstract    In August 2013 Annals of Oncology， it published the 13th St Gallen Consensus on the Primary Therapy of Early Breast Cancer. Major issues that have been highlighted included: multi-gene molecular assays are readily available and there is a trend towards basing chemotherapy decisions for patients with luminal disease on these genomic results rather than the surrogate subtype definitions; refining its earlier approach to the classification and management of luminal disease in the absence of amplification or overexpression of the Human Epidermal growth factor Receptor 2(HER2) oncogene; supporting less extensive surgery to the axilla and shorter durations of radiation therapy. The recommendations based on the genomic analysis represented the significant alteration of major concepts of personalized treatment in the field of early breast cancer.